CDGEN1.16

General#

Cell Line

hPSCreg Name
ICANi001-A
Alternative name(s)
CDGEN1.16
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 1st October 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator INSERM U1166-Institute of Cardiometabolism And Nutrition (ICAN)
Owner INSERM U1166-Institute of Cardiometabolism And Nutrition (ICAN)
Distributors
Derivation country France

External Databases

BioSamples SAMEA10202562

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: allowed
Commercial: not allowed
Subclones

Donor Information#

General Donor Information

Sex female
Age of donor (at collection) 50-54
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
hypertrophic cardiomyopathy
The donor is a carrier of a disease-associated mutation and affected.
Stage
NYHA 4
Synonyms
  • Asymmetric Septal Hypertrophies
  • Hypertrophic Obstructive Cardiomyopathies
  • Cardiomyopathy, hypertrophic
  • Subvalvular Stenosis, Idiopathic Hypertrophic
  • Hypertrophic Obstructive Cardiomyopathy
  • HYPERTR OBSTR CARDIOMYOP
  • hyper. obst. cardiomyopathy
  • SUBVALV STENOSIS
  • HCM - Hypertrophic cardiomyopathy
  • IDIOPATHIC HYPERTROPHIC SUBVALV STENOSIS
  • Obstructive Cardiomyopathy, Hypertrophic
  • Hypertrophies, Asymmetric Septal
  • Hypertrophic Cardiomyopathies
  • Cardiomyopathies, Hypertrophic Obstructive
  • Hypertrophic cardiomyopathy (disorder)
  • HOCM - Hypertrophic obstructive cardiomyopathy
  • Primary hypertrophic cardiomyopathy
  • Idiopathic Hypertrophic Subvalvular Stenosis
  • IHSS
  • primary hypertrophic cardiomyopathy (disorder) [Ambiguous]
  • Idiopathic Hypertrophic Subaortic Stenosis
  • Obstructive cardiomyopathy
  • SUBVALV STENOSIS IDIOPATHIC HYPERTROPHIC
  • Hypertrophy, Asymmetric Septal
  • Hypertrophic obstructive cardiomyopathy (disorder)
  • Septal Hypertrophy, Asymmetric
  • Cardiomyopathies, Hypertrophic
  • IHSSs
  • hypertrophic myocardiopathy
  • Cardiomyopathy, Hypertrophic Obstructive
  • HCM
  • Obstructive Cardiomyopathies, Hypertrophic
  • Asymmetric Septal Hypertrophy
  • Septal Hypertrophies, Asymmetric
  • hypertrophic subaortic stenosis
  • obstructive hypertrophic cardiomyopathy
  • hypertrophic obstructive cardiomyopathy
  • hypertrophic cardiomyopathy
show more synonyms
Genetic variants
14q11.2
NM_000257.4:c.1208G>T
NP_000248.2:p.Arg403Leu
Heterozygous
VCV000014101.6

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

External Databases (Donor)

BioSamples SAMEA10202562

Ethics#

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? No
Provide contact information of the holder of the original Donor Information Sheet: v.fontaine@ican-institute.org
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? ANSM
Approval number 151277B-62
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

Source cell type
skin fibroblast
Age of donor (at collection) 50-54
Passage number reprogrammed 4

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Mechanically
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SOX2
Yes
Alkaline Phosphatase
Yes
Self-renewal
Negative
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Differentiation Potency
Cardiac Muscle Cell
Ont Id: CL_0000746
In vitro directed differentiation

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Karyotype_CDGEN1.16
Passage number: 20
Karyotyping method: G-Banding

Other Genotyping (Cell Line)